DGX240719C145000
- 0.45
- +0.13+40.63%
Quest Diagnostics Newsroom
Citi Upgrades Illumina, Quest, Agilent to Buy, Downgrades Avantor
Quest Diagnostics Analyst Ratings
Citigroup Upgrades Quest Diagnostics to Buy From Neutral, Adjusts Price Target to $165 From $145
Analysts' Opinions Are Mixed on These Healthcare Stocks: CureVac (CVAC), Insmed (INSM) and Quest Diagnostics (DGX)
Quest Diagnostics Analyst Ratings
Baird Adjusts Price Target on Quest Diagnostics to $153 From $145, Maintains Neutral Rating
Barclays Sticks to Their Hold Rating for Quest Diagnostics (DGX)
Buy Rating Affirmed: Quest Diagnostics' Strategic Acquisition of LifeLabs Poised to Boost Growth and Profitability
Nephron Adjusts Price Target on Quest Diagnostics to $155 From $152
Quest Diagnostics Analyst Ratings
JPMorgan Adjusts Price Target on Quest Diagnostics to $155 From $152
Quest Diagnostics Inc: J.P. Morgan raises price target from $152 to $155
Argus Adjusts Price Target on Quest Diagnostics to $215 From $163, Keeps Buy Rating
Argus Raises Quest Diagnostics' Price Target to $163 From $155
Buy Rating Affirmed for Quest Diagnostics on Strong Earnings Visibility and Growth Prospects
Baird Adjusts Quest Diagnostics' Price Target to $144 From $138
Piper Sandler Reaffirms Their Hold Rating on Quest Diagnostics (DGX)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Apellis Pharmaceuticals (APLS), Quest Diagnostics (DGX) and Healthcare Services (HCSG)
Quest Diagnostics: A Hold Rating Amid Solid Earnings and Strategic Caution
Barclays: Maintaining the Quest Diagnostics (DGX.US) rating, adjusted from a wait-and-see shareholding rating to a shareholding wait-and-see rating, and the target price was adjusted from $138.00 to $144.00.